title: Novel angiogenesis inhibitors in nonsmall cell lung cancer.
abstract: OBJECTIVE
  The fact that growth and spread of tumours are dependent on angiogenesis has led to the investigation of the role of antiangiogenic agents in the therapeutic strategies for thoracic tumours such as nonsmall cell lung cancer (NSCLC). This review summarizes and evaluates the recent developments in this field.
  
  
  RESULTS
  Bevacizumab, an antivascular endothelial growth factor antibody, has been approved for the treatment of patients with advanced NSCLC of nonsquamous histology in combination with a platinum-containing chemotherapy. Like in other cancer entities, the antiangiogenic concept in NSCLC comprises maintenance therapy with the antiangiogenic compound until disease progression. Moreover, over the last years, new antiangiogenic agents have been tested in clinical trials in NSCLC patients. Recent trials have demonstrated the efficacy of antiangiogenic agents in combination with docetaxel in the second-line setting.
  
  
  CONCLUSIONS
  These studies - together with experiences from other cancer entities - have revived the field of antiangiogenic treatment in lung cancer.
authors.affiliation: aDepartment of Thoracic Oncology, LungenClinic Großhansdorf, Grosshansdorf bAirway Research Center North, German Center for Lung Research (DZL), Heidelberg, Germany.
authors.forename: Niels
authors.initials: N
authors.lastname: Reinmuth
authors.forename: David
authors.initials: D
authors.lastname: Heigener
authors.forename: Martin
authors.initials: M
authors.lastname: Reck
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D000096662:Ramucirumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077143:Docetaxel; D007211:Indoles; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D000096662:Ramucirumab; C530716:nintedanib